Home4507 • TYO
Shionogi & Co Ltd
Â¥2,253.00
Jan 10, 6:15:00 PM GMT+9 · JPY · TYO · Disclaimer
StockGLeaf logoClimate leaderJP listed securityJP headquartered
Previous close
Â¥2,210.50
Day range
¥2,223.50 - ¥2,288.00
Year range
¥1,944.66 - ¥2,712.33
Market cap
2.00T JPY
Avg Volume
2.06M
P/E ratio
12.47
Dividend yield
2.52%
Primary exchange
TYO
CDP Climate Change Score
A
Market news
Financials
Income Statement
Revenue
Net income
(JPY)Sep 2024Y/Y change
Revenue
116.38B-4.00%
Operating expense
52.93B-3.66%
Net income
52.50B9.30%
Net profit margin
45.1113.86%
Earnings per share
——
EBITDA
53.13B-5.14%
Effective tax rate
8.28%—
Total assets
Total liabilities
(JPY)Sep 2024Y/Y change
Cash and short-term investments
303.40B20.22%
Total assets
1.46T3.34%
Total liabilities
145.93B-18.09%
Total equity
1.31T—
Shares outstanding
850.69M—
Price to book
1.32—
Return on assets
8.22%—
Return on capital
9.10%—
Net change in cash
(JPY)Sep 2024Y/Y change
Net income
52.50B9.30%
Cash from operations
45.30B220.14%
Cash from investing
-17.63B47.30%
Cash from financing
-1.11B94.50%
Net change in cash
21.45B158.43%
Free cash flow
8.02B135.46%
About
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Founded
Mar 17, 1878
Headquarters
Employees
4,959
Search
Clear search
Close search
Google apps
Main menu